The investment round was backed by Araya Ventures, Morgan Stanley, Techstars and G Fund to fuel platform innovation and global growth.
"MyARC was built for modern day fitness creators, giving them the tools they need to grow without burning out. The traditional online fitness model has left creators trapped between low-value generic products and unsustainable personal coaching. With this platform, they can scale their impact and income without sacrificing quality."
The Series A round was led by Acton Capital to accelerate artificial intelligence features and international growth.
"Eolas has always been about solving a very practical problem: giving healthcare professionals fast, reliable access to the knowledge they need, when they need it. This is especially important in acute settings, where staff are under pressure to make decisions quickly and safely – particularly in the winter. As AI develops, the next phase is about making that access even more usable, so staff can ask a question and get a clear, evidence-backed answer straight away, in plain language."
The company has also appointed James Hardy as an investor and strategic advisor.
"What really stood out to me was the strength of the team and the clarity of the model. incentifi is built around improving healthier lives while delivering a clear return for employers and partners. Having seen first-hand at Bioniq how impactful it can be when wellbeing and business objectives truly align, incentifi delivers exactly that. I’m excited to be part of the journey ahead."
The financing extension brings Nuclera's total Series C funding to $87m and will advance antibody engineering capabilities.
"Since our initial investment, Nuclera has made meaningful progress in expanding the capabilities, adoption, and global reach of the eProtein Discovery platform. The extension of the system into full-format antibody expression, purification, and binding validation represents a significant step forward, particularly as biologics discovery becomes increasingly driven by AI-enabled workflows that require scalable, high-quality datasets. Elevage is proud to continue supporting Nuclera as it evolves into a foundational platform for protein and antibody engineering, helping researchers accelerate discovery timelines and reduce friction across the drug development process."
The oversubscribed financing was led by Ahren Innovation Capital and will support preclinical validation and platform development.
"Partnering with the team at o2h discovery is a fantastic milestone for OutSee as we look ahead to commencing our first drug discovery programme and showcasing the potential of our Nomaly platform to revolutionise target discovery. The agreement is testament to the strength of our technology and, in combination with the closure of our oversubscribed seed funding round, kicks off a very exciting year. Thank you to our investors and supporters for their continued support, and the hard work and dedication of our team."
